GNPX GENPREX INC US FDA Inspections 8-K Filing 2025 - Clinical Trials On May 6, 2025, Genprex, Inc. announced an exclusive patent license agreement with UTHealth Houston, granting commercial rights for its gene therapy, Reqorsa®, aimed at treating glioblastoma. The therapy has shown promising preclinical efficacy in reducing tumor cell viability and migration.Get access to all SEC 8-K filings of the GENPREX INC